

Request a meeting for your  
ACR Affiliate Society today!

PeerView  
Live

## RHEUMATOLOGY

### Rheumatology, Immunology, and Immuno-Oncology Intersect: Navigating the Complexities of Immune Checkpoint Inhibition, Autoimmunity, and Immune-Related Adverse Events

*How Can Rheumatologists Help Minimize the Risks and Maximize the Benefits  
of Cancer Immunotherapies?*

#### Activity Overview

Join us for one of the live, in-person meetings we will be carrying out at ACR Affiliate Societies. A nationally recognized expert will provide a concise update on the immuno-oncology revolution that has occurred over the last few years and what the key implications are for rheumatology professionals. Learn about how the immune system is being successfully harnessed in the treatment of an increasing number of cancers, the unique spectrum of immune-related adverse events that can occur in patients with cancer undergoing treatment with the new class of immune checkpoint inhibitors, and the central role that rheumatology professionals have in helping to evaluate and manage these patients to minimize the risks and maximize the benefits from the novel cancer immunotherapies.

#### Activity Description

Cancer immunotherapy represents a major advance in oncology, and also has increasing relevance in rheumatology. Great success has been achieved in recent years with the novel class of immune checkpoint inhibitors in the treatment of a range of cancer types. Attendant to the success of these immunotherapeutic agents are a range of new and unique adverse events of inflammatory nature, with some having documented autoimmune mechanisms. These immune-related adverse events (irAEs) can affect any organ system, and rheumatic irAEs are part of the spectrum as well. Timely recognition and effective management of irAEs is essential in ensuring that patients with cancer derive the maximum benefit from the anti-tumor efficacy of the immune checkpoint inhibitors.

Rheumatology professionals can expect to encounter more and more patients with rheumatic adverse events induced by immune checkpoint inhibitors and other novel immunotherapies as a consequence of the anticipated exponential growth in the use of these agents alone and in combinations to treat an expanding list of different malignancies. As well, rheumatologists have an important role to play in evaluating more challenging populations of patients with cancer, including those with underlying autoimmune conditions, to determine whether or not they could safely receive immune checkpoint inhibitor therapy and potentially benefit from this class of agents.

#### Learning Objectives

Upon completion of this activity, participants will be able to:

- Summarize the basic principles of harnessing the human immune system in the treatment of cancer, as well as the mechanistic aspects of immune checkpoint inhibition in cancer therapy and development of immune-related adverse events (irAEs) associated with immunotherapies
- Assess the potential benefits and risks of cancer immunotherapies for patients with cancer who have pre-existing autoimmune conditions to determine candidacy for cancer immunotherapy
- Describe the spectrum of rheumatic and other irAEs associated with the immune checkpoint inhibitors, including incidence and presentation
- Discuss the general and organ/site-specific recommendations for evaluation, diagnosis, grading, and management of irAEs, including the more and less commonly occurring rheumatic irAEs
- Evaluate whether or not cancer immunotherapies can be safely considered for patients with cancer who have concomitant autoimmune conditions, based on individualized assessment of risks and benefits in collaboration with oncology
- Implement recommended strategies for triage, evaluation, diagnosis, and management of rheumatic and other relevant irAEs in rheumatology practice in collaboration with oncology

#### CHAIR & PRESENTER



#### Leonard H. Calabrese, DO

Professor of Medicine, Cleveland Clinic  
Lerner College of Medicine of Case Western  
Reserve University  
RJ Fasenmyer Chair of Clinical Immunology  
Vice Chairman, Department of Rheumatic  
and Immunologic Diseases  
Cleveland, Ohio

#### Target Audience

This activity has been designed to meet the educational needs of rheumatologists, rheumatology nurses, physician assistants, and other healthcare professionals involved in the care of patients with cancer and rheumatic conditions.

Visit  
[PeerView.com/Rheum19](https://www.peerview.com/Rheum19)  
for more details, and request  
your meeting today!

## PARTICIPATING FACULTY

Full faculty details available upon request

#### Leonard H. Calabrese, DO

Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University  
RJ Fasenmyer Chair of Clinical Immunology  
Vice Chairman, Department of Rheumatic and Immunologic Diseases  
Cleveland, Ohio

For a complete faculty list, contact Dede Lewis  
at [dede.lewis@peerview.com](mailto:dede.lewis@peerview.com).

#### Providership, Credit & Support

##### Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

##### MOC Statement

 Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME's Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

##### Nurses

Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Successful completion of this continuing nursing education activity will be awarded 1.0 contact hour(s).

This CME/MOC/CNE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported through an educational grant from Bristol-Myers Squibb.

